Please wait while the formulary information is being retrieved.
ONDANSETRON HCL (ONDANSETRON HCL/PF)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Prevention of radiation-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Zofran Tablet
- Ondansetron Hcl Tablet
- Ondansetron Hcl Iv
- Ondansetron Hcl Intravenous Solution
- Ondansetron Hcl (pf) Injection Solution
- Ondansetron Hcl (pf) Injection
- By Indication
4 mg tablet
- 2 tablets (8 mg) by oral route 2 times per day
8 mg tablet
- 1 tablet (8 mg) by oral route every 8 hours for 2 days
24 mg tablet
- 1 tablet (24 mg) by oral route 30 minutes before the start of single-day chemotherapy
4 mg tablet
- 2 tablets (8 mg) by oral route 2 times per day
8 mg tablet
- 1 tablet (8 mg) by oral route every 8 hours for 2 days
2 mg/mL intravenous solution
- Inject 2 milliliters (4 mg) over 2-4 minute(s) by intravenous route for nausea or vomiting after surgery
2 mg/mL intravenous solution
- Inject 2 milliliters (4 mg) over 2-4 minute(s) by intravenous route for nausea or vomiting after surgery
(PF) 4 mg/2 mL injection solution
- Dosage information is not available
4 mg/2 mL injection solution
- Dosage information is not available
4 mg/2 mL injection solution
- Dosage information is not available
Cancer chemotherapy-induced nausea and vomiting
- Infuse 0.15 mg/kg by intravenous route every 4 hours for 12 hours
- Infuse 1 mg/hour by continuous infusion route
- Infuse 1 mg/hour by continuous infusion route for up to 24 hours
- 1 tablet (8 mg) by oral route every 8 hours
- 2 tablets (8 mg) by oral route every 8 hours
Excessive vomiting in pregnancy
- Infuse 1 mg/hour by continuous infusion route
- Infuse 1 mg/hour by continuous infusion route for up to 24 hours
Prevention of chemotherapy-induced nausea and vomiting
- Infuse 0.15 mg/kg by intravenous route every 4 hours for 12 hours
- Infuse 1 mg/hour by continuous infusion route
- Infuse 1 mg/hour by continuous infusion route for up to 24 hours
- 2 tablets (8 mg) by oral route every 12 hours
- 1 tablet (8 mg) by oral route 2 times per day
- 1 tablet (8 mg) by oral route every 12 hours
- 2 tablets (8 mg) by oral route 2 times per day
- 1 tablet (8 mg) by oral route 2 times per day for 1 day
- 1 tablet (8 mg) by oral route 2 times per day for 2 days
- 1 tablet (8 mg) by oral route every 12 hours for 1 day
- 1 tablet (8 mg) by oral route every 12 hours for 2 days
- 1 tablet (8 mg) by oral route every 8 hours
- 1 tablet (8 mg) by oral route every 8 hours for 1 day
- 1 tablet (8 mg) by oral route every 8 hours for 2 days
- 1 tablet (8 mg) by oral route 30 minutes before the start of chemotherapy, then 1 tablet (8 mg) eight hours after the first dose
- 2 tablets (8 mg) by oral route 2 times per day for 1 day
- 2 tablets (8 mg) by oral route 2 times per day for 2 days
- 2 tablets (8 mg) by oral route every 12 hours for 1 day
- 2 tablets (8 mg) by oral route every 12 hours for 2 days
- 2 tablets (8 mg) by oral route 30 minutes before the start of chemotherapy, then 2 tablets (8 mg) eight hours after the first dose
- Infuse 0.15 mg/kg over 15 minute(s) by intravenous route beginning 30Minutes before the start of chemotherapy; then 0.15 mg/kg 4 and 8Hours after the first dose
- Infuse 8 mg over 15 minute(s) by intravenous route beginning 30 minutes before chemotherapy, followed immediately by a continuous infusion of 1 mg/hour for up to 24 hours
Prevention of post-operative nausea and vomiting
- Inject 2 milliliters (4 mg) over 2-5 minute(s) by intravenous route immediately before induction of anesthesia
- Inject 2 milliliters (4 mg) by intramuscular route immediately beforeinduction of anesthesia
- Inject 2 milliliters (4 mg) over 2-4 minute(s) by intravenous route for nausea or vomiting after surgery
- Inject 2 milliliters (4 mg) by intramuscular route for nausea or vomiting after surgery
- 2 tablets (16 mg) by oral route 1 hour before induction of anesthesia
Prevention of radiation-induced nausea and vomiting
- 1 tablet (8 mg) by oral route 1-2 hours before radiation, with additional doses every 8 hours after the first dose for 1-2 days after completion of radiation
- 1 tablet (8 mg) by oral route 1-2 hours before radiation, with additional doses every 8 hours after the first dose for each day radiation is given
- 2 tablets (8 mg) by oral route 1-2 hours before radiation, with additional doses every 8 hours after the first dose for 1-2 days aftercompletion of radiation
- 2 tablets (8 mg) by oral route 1-2 hours before radiation, with additional doses every 8 hours after the first dose for each day radiation is given
- 2 tablets (8 mg) by oral route 3 times per day
- 1 tablet (8 mg) by oral route 3 times per day
- 1 tablet (8 mg) by oral route every 8 hours
- 1 tablet (8 mg) by oral route every 8 hours for 1 day
- 1 tablet (8 mg) by oral route every 8 hours for 2 days
- 1 tablet (8 mg) by oral route 1-2 hours prior to radiation therapy
- 2 tablets (8 mg) by oral route every 8 hours
- 2 tablets (8 mg) by oral route every 8 hours for 1 day
- 2 tablets (8 mg) by oral route every 8 hours for 2 days
- 2 tablets (8 mg) by oral route 1-2 hours prior to radiation therapy
- Apokyn
- apomorphine
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- artemether-lumefantrine
- Coartem
- Cordarone
- disopyramide
- dronedarone
- droperidol
- Geodon
- Multaq
- Nexterone
- Norpace
- Norpace Cr
- Orap
- Pacerone
- pimozide
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Ablavar
- Advair Diskus
- Advair Hfa
- alfuzosin
- amantadine HCl
- Anzemet
- Astagraf Xl
- azithromycin
- bedaquiline
- Cardene Iv
- Cardene Iv In Dextrose
- Cardene Iv In Sodium Chloride
- Cardene Sr
- chloroquine phosphate
- chlorpromazine
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clozapine
- Clozaril
- Complera
- Conzip
- Corvert
- crizotinib
- dasatinib
- dolasetron
- Edurant
- Effexor Xr
- emtricitab-rilpivirine-tenofov
- eribulin
- ezogabine
- Fareston
- Fazaclo
- felbamate
- Felbatol
- flecainide
- fluticasone-salmeterol
- foscarnet
- Foscavir
- gadofosveset trisodium
- granisetron
- granisetron (PF)
- Granisol
- Halaven
- Hecoria
- ibutilide fumarate
- indapamide
- Invega
- Invega Sustenna
- Invirase
- isradipine
- Istodax
- Kaletra
- lapatinib
- Levitra
- lithium carbonate
- lithium citrate
- Lithobid
- lopinavir-ritonavir
- moexipril
- moexipril-hydrochlorothiazide
- Nebupent
- Nexavar
- nicardipine
- nicardipine in dextrose,iso-os
- nicardipine in NaCl (iso-os)
- nilotinib
- norfloxacin
- Noroxin
- Noxafil
- octreotide acetate
- ofloxacin
- paliperidone
- paliperidone palmitate
- pasireotide
- pazopanib
- Pentam
- pentamidine
- posaconazole
- Potiga
- procainamide
- Prograf
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- rilpivirine
- romidepsin
- Rythmol
- salmeterol
- Sancuso
- Sandostatin
- Sandostatin Lar Depot
- saquinavir mesylate
- Serevent Diskus
- Seroquel
- Seroquel Xr
- Signifor
- Sirturo
- Soltamox
- sorafenib
- Sprycel
- sunitinib
- Sutent
- Synapryn
- tacrolimus
- tamoxifen
- Tasigna
- telavancin
- tetrabenazine
- tizanidine
- toremifene
- tramadol
- tramadol-acetaminophen
- tramadol-glucosamine
- Tykerb
- Ultracet
- Ultram
- Ultram Er
- Uniretic
- Univasc
- Uroxatral
- vardenafil
- vemurafenib
- venlafaxine
- Versacloz
- Vfend
- Vfend Iv
- Vibativ
- voriconazole
- Votrient
- Xalkori
- Xenazine
- Zanaflex
- Zelboraf
- Zithromax
- Zithromax Tri-pak
- Zithromax Z-pak
- Zmax
- Congenital long QT syndrome
- Prolonged QT interval
- Torsades de pointes
Contraindicated
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Neuroleptic malignant syndrome
- Prolonged QT interval
- Serotonin syndrome
- Severe hepatic disease
Severe
Moderate
- Bradycardia
- Chronic heart failure
- Extrapyramidal disease
- Seizure disorder
ONDANSETRON HCL (ONDANSETRON HCL/PF)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Prevention of radiation-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- None
- Chills
- Constipation
- Diarrhea
- Drowsy
- Fever
- Headache disorder
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Dizziness
- Drowsy
- Fatigue
- General weakness
- Paresthesia
- Pruritus of skin
- Sensation of cold
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal ECG
- Abnormal hepatic function tests
- Acquired dystonia
- Acute hepatic failure
- Anaphylaxis
- Angina
- Angioedema
- Atrial fibrillation
- Blurred vision
- Bradycardia
- Bronchospastic pulmonary disease
- Dyspnea
- Extrapyramidal disease
- Hypersensitivity drug reaction
- Hypotension
- Hypoxia
- Injection site sequelae
- Laryngeal edema
- Prolonged QT interval
- Second degree atrioventricular heart block
- Serotonin syndrome
- Shock
- ST segment changes
- Stevens-johnson syndrome
- Syncope
- Tachycardia
- Torsades de pointes
- Toxic epidermal necrolysis
- Transient blindness
- Ventricular premature beats
Less Severe
- Agitation
- Angina
- Arthralgias
- Blurred vision
- Chest discomfort
- Flushing
- Hiccups
- Hyperhidrosis
- Lethargy
- Palpitations
- Paresthesia
- Pruritus of skin
- Purpura
- Skin rash
- Symptoms of anxiety
- Tachycardia
- Urinary retention
- Urticaria
- Xerostomia
Contraindicated
None
Severe Precaution
Ondansetron (Select routes)
Limited information age < 30 days. Longer half-life in infants. Monitor closely.
Longer half-life in age < 4 months. Monitor closely.
- 1 Day – 29 Days
- Limited information age < 30 days. Longer half-life in infants. Monitor closely.
- Longer half-life in age < 4 months. Monitor closely.
- 30 Days – 119 Days
- Limited information age < 30 days. Longer half-life in infants. Monitor closely.
- Longer half-life in age < 4 months. Monitor closely.
Management or Monitoring Precaution
None
Ondansetron
- Severity Level:
2
- Additional Notes: Insufficient human data available; no developmental toxicity seen in animals
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ondansetron
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ondansetron
Cardiovascular-The elderly are more prone to QT prolongation due to multiple meds and iatrogenic hypokalemia, hypomagnesemia; correct electrolytes before giving oral or IV ondansetron. Neuro/Psych-The elderly may be more prone to extrapyramidal reactions associated with IV doses.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: Y
No Known Risk
None
- None
Formulary Reference Tool